116 related articles for article (PubMed ID: 27044355)
1. Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer.
Takayama T; Kubo T; Morikawa A; Morita T; Nagano O; Saya H
Med Oncol; 2016 May; 33(5):45. PubMed ID: 27044355
[TBL] [Abstract][Full Text] [Related]
2. Dose-escalation study for the targeting of CD44v
Shitara K; Doi T; Nagano O; Imamura CK; Ozeki T; Ishii Y; Tsuchihashi K; Takahashi S; Nakajima TE; Hironaka S; Fukutani M; Hasegawa H; Nomura S; Sato A; Einaga Y; Kuwata T; Saya H; Ohtsu A
Gastric Cancer; 2017 Mar; 20(2):341-349. PubMed ID: 27055559
[TBL] [Abstract][Full Text] [Related]
3. Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer.
Ogihara K; Kikuchi E; Okazaki S; Hagiwara M; Takeda T; Matsumoto K; Kosaka T; Mikami S; Saya H; Oya M
Cancer Sci; 2019 Apr; 110(4):1431-1441. PubMed ID: 30719824
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).
Shitara K; Doi T; Nagano O; Fukutani M; Hasegawa H; Nomura S; Sato A; Kuwata T; Asai K; Einaga Y; Tsuchihashi K; Suina K; Maeda Y; Saya H; Ohtsu A
Gastric Cancer; 2017 Nov; 20(6):1004-1009. PubMed ID: 28466360
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
Miyoshi S; Tsugawa H; Matsuzaki J; Hirata K; Mori H; Saya H; Kanai T; Suzuki H
Anticancer Res; 2018 Nov; 38(11):6163-6170. PubMed ID: 30396933
[TBL] [Abstract][Full Text] [Related]
6. Convection-enhanced delivery of sulfasalazine prolongs survival in a glioma stem cell brain tumor model.
Haryu S; Saito R; Jia W; Shoji T; Mano Y; Sato A; Kanamori M; Sonoda Y; Sampetrean O; Saya H; Tominaga T
J Neurooncol; 2018 Jan; 136(1):23-31. PubMed ID: 28929335
[TBL] [Abstract][Full Text] [Related]
7. [Redox regulation in cancer stem cells].
Saya H
Nihon Rinsho; 2015 May; 73(5):790-4. PubMed ID: 25985632
[TBL] [Abstract][Full Text] [Related]
8. Endothelial-Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary Hypertension.
Isobe S; Kataoka M; Endo J; Moriyama H; Okazaki S; Tsuchihashi K; Katsumata Y; Yamamoto T; Shirakawa K; Yoshida N; Shimoda M; Chiba T; Masuko T; Hakamata Y; Kobayashi E; Saya H; Fukuda K; Sano M
Am J Respir Cell Mol Biol; 2019 Sep; 61(3):367-379. PubMed ID: 30897333
[TBL] [Abstract][Full Text] [Related]
9. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
[TBL] [Abstract][Full Text] [Related]
10. Redox regulation in stem-like cancer cells by CD44 variant isoforms.
Nagano O; Okazaki S; Saya H
Oncogene; 2013 Oct; 32(44):5191-8. PubMed ID: 23334333
[TBL] [Abstract][Full Text] [Related]
11. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
Ma MZ; Chen G; Wang P; Lu WH; Zhu CF; Song M; Yang J; Wen S; Xu RH; Hu Y; Huang P
Cancer Lett; 2015 Nov; 368(1):88-96. PubMed ID: 26254540
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs.
Schipper LG; Fransen J; Barrera P; Van Riel PL
Rheumatology (Oxford); 2009 Jul; 48(7):828-33. PubMed ID: 19458163
[TBL] [Abstract][Full Text] [Related]
13. Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer.
Yun EJ; Zhou J; Lin CJ; Hernandez E; Fazli L; Gleave M; Hsieh JT
Clin Cancer Res; 2016 Feb; 22(3):670-9. PubMed ID: 26490309
[TBL] [Abstract][Full Text] [Related]
14. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
[TBL] [Abstract][Full Text] [Related]
15. Sulfasalazine, a potent cystine-glutamate transporter inhibitor, enhances osteogenic differentiation of canine adipose-derived stem cells.
Itoh H; Tani K; Sunahara H; Nemoto Y; Nakaichi M; Horikirizono H; Itamoto K
J Vet Med Sci; 2023 Nov; 85(11):1237-1244. PubMed ID: 37866885
[TBL] [Abstract][Full Text] [Related]
16. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer.
Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K
Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396
[TBL] [Abstract][Full Text] [Related]
18. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.
Jansen G; van der Heijden J; Oerlemans R; Lems WF; Ifergan I; Scheper RJ; Assaraf YG; Dijkmans BA
Arthritis Rheum; 2004 Jul; 50(7):2130-9. PubMed ID: 15248210
[TBL] [Abstract][Full Text] [Related]
19. Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9(+) cancer stem cells in ulcerative colitis-related cancer.
Seishima R; Okabayashi K; Nagano O; Hasegawa H; Tsuruta M; Shimoda M; Kameyama K; Saya H; Kitagawa Y
Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):487-93. PubMed ID: 26775891
[TBL] [Abstract][Full Text] [Related]
20. Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials.
Weinblatt ME; Reda D; Henderson W; Giobbie-Hurder A; Williams D; Diani A; Docsa S
J Rheumatol; 1999 Oct; 26(10):2123-30. PubMed ID: 10529127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]